Next Level Private LLC Has $2.54 Million Position in Bristol Myers Squibb Company $BMY

Next Level Private LLC decreased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 25.5% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 56,300 shares of the biopharmaceutical company’s stock after selling 19,299 shares during the period. Next Level Private LLC’s holdings in Bristol Myers Squibb were worth $2,541,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in BMY. Trifecta Capital Advisors LLC acquired a new stake in Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Darwin Wealth Management LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter valued at $25,000. Harbor Capital Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 107.2% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 313 shares during the last quarter. REAP Financial Group LLC increased its position in shares of Bristol Myers Squibb by 202.8% during the second quarter. REAP Financial Group LLC now owns 639 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 428 shares during the period. Finally, CBIZ Investment Advisory Services LLC lifted its holdings in Bristol Myers Squibb by 66.0% in the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock valued at $35,000 after buying an additional 231 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on BMY shares. Guggenheim reiterated a “buy” rating on shares of Bristol Myers Squibb in a report on Tuesday, December 23rd. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $57.00 target price (up previously from $51.00) on shares of Bristol Myers Squibb in a research note on Tuesday, December 2nd. Wall Street Zen raised Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Scotiabank restated a “sector perform” rating and set a $53.00 price target (up from $45.00) on shares of Bristol Myers Squibb in a report on Thursday, December 4th. Finally, BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research note on Monday, November 17th. Six research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $56.08.

Bristol Myers Squibb Trading Down 1.4%

NYSE BMY opened at $55.95 on Friday. The company has a quick ratio of 1.17, a current ratio of 1.27 and a debt-to-equity ratio of 2.39. Bristol Myers Squibb Company has a 52 week low of $42.52 and a 52 week high of $63.33. The business has a 50 day moving average price of $50.73 and a 200-day moving average price of $47.73. The company has a market cap of $113.89 billion, a price-to-earnings ratio of 18.90, a P/E/G ratio of 9.43 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The business had revenue of $12.22 billion during the quarter, compared to analyst estimates of $11.75 billion. During the same quarter in the previous year, the business posted $1.80 EPS. Bristol Myers Squibb’s quarterly revenue was up 2.8% on a year-over-year basis. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. As a group, equities analysts expect that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Shareholders of record on Friday, January 2nd will be paid a dividend of $0.63 per share. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date is Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 85.14%.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY from Neutral to Buy and raised its price target to $65, which boosts near-term upside and investor sentiment. UBS upgrades Bristol-Myers Squibb (BMY)
• Positive Sentiment: Piper Sandler reiterated its Buy rating, reinforcing analyst support and demand-side confidence for the shares. Piper Sandler Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY)
• Positive Sentiment: Company-backed real-world lung cancer data was reported to add support to the nivolumab growth story, which could underpin oncology revenue momentum. Bristol-Myers Squibbs Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
• Positive Sentiment: BMY added a new immunotherapy combo bet in small-cell lung cancer (SCLC), expanding potential label and market opportunities for its immuno-oncology franchise. Bristol Myers Squibb Adds New Immunotherapy Combo Bet in Small Cell Lung Cancer
• Positive Sentiment: BMS quietly launched a first-in-human study of BMS-986521, indicating continued pipeline expansion and optionality beyond core drugs. Bristol-Myers Squibb Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
• Neutral Sentiment: Coverage pieces are reassessing BMY valuation as shares have run up and the profitability narrative evolves; this highlights debate between growth expectations and near-term multiples. Assessing Bristol Myers Squibb (BMY) Valuation As Shares Gain And Profitability Narrative Evolves
• Neutral Sentiment: An Argus/analyst report was published (general coverage), which may influence investor views but contains no single market-moving surprise. Analyst Report: Bristol-Myers Squibb Co.
• Neutral Sentiment: A broader healthcare stock roundup suggested taking advantage of select names; this is general market commentary rather than BMY-specific guidance. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Negative Sentiment: A feature questioned whether current pricing reflects renewed patent-cliff risks for Opdivo and Eliquis, which could pressure long-term revenue if generic competition accelerates. Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.